AlgiPharma CMO Dr Yngve Mikkelsen Advances Research into Responsible AI in Medicine Artificial intelligence has enormous potential in medicine, but healthcare presents challenges that do not exist in many other industries. Medical data are complex, highly variable and sensitive, and an AI system that performs well in one setting may not necessarily work equally well […]
AlgiPharma is attending the 17th Global Drug Delivery & Formulation (DDF) Summit 2026 in Berlin from May 18–20, 2026. This event is a valuable opportunity for AlgiPharma to meet industry experts to discuss advancements in drug delivery, and formulation. We are looking forward to using the opportunity to further our drug delivery program through discussions […]
Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus We’re encouraged to see strong engagement with our recent scientific publication which has now surpassed 1,000 views. The work was carried out in collaboration with Steve Hart’s first-class team at the Department of Genetics […]
Alginate-Amphotericin B bifunctional conjugates have improved solubility and reduced toxicity We’re very pleased to announce a new publication of AlgiPharma’s technology that highlights the potential to improve drug delivery through conjugation chemistry with AlgiPharma’s low molecular weight alginate oligosaccharides, creating novel bifunctional antimicrobial compounds. The work was carried out in collaboration with first-class research teams […]
AlgiPharma attended and presented at this year’s Partnership Opportunities in Drug Delivery (PODD) conference in Boston. Dr. Yngve Mikkelsen (CMO) had the opportunity to present AlgiPharma’s work on alginate oligosaccharides as a next-generation delivery platform for GLP-1 receptor agonists and beyond. Our data demonstrate how AlgiPharma’s technology enhances oral bioavailability and improves mucus translocation for […]
AlgiPharma is attending the 8th International Symposium on Solid Oral Dosage Forms organised by the Swedish Pharmaceutical Society and will take place on 22nd – 25th Sept at the AstraZeneca site in Mölndal, Sweden. Attendees from AlgiPharma will be by our CSO, Dr. Philip Rye, and Dr Ivana Smiljanic our Quality Manager. We are looking […]
AlgiPharma is attending the European Cystic Fibrosis Conference taking place on 4th – 6th June in Milan Italy. Looking forward to catching up with CF colleagues and using the opportunity for further discussions with potential commercial partners. Attendees from AlgiPharma will be our CEO, Yngvar Berg, CSO, Dr. Philip Rye, and Dr Charles Johnson from […]
AlgiPharma presenting at Formulation and Delivery 2024, London, UK We are delighted to have been invited to speak at the Formulation & Delivery 2024 conference, taking place 25th – 26th April in London, UK. AlgiPharma will have two separate presentations highlighting it’s alginate technology for use in the drug delivery of lipid nanoparticles by inhalation […]
R&D Project Manager at AlgiPharma Application Deadline: 28.01.2024 The candidate will proactively manage the day-to-day running of multiple R&D projects, coordinating with key internal and external stakeholders to advance our portfolio of alginate oligosaccharide technologies for drug delivery, drug conjugates and stand-alone API for cystic fibrosis, COPD and infectious diseases. In addition to the basic […]
We are delighted to have been invited to speak at the 2nd Lipid Nanoparticle Development Europe Summit, taking place 17-19th October 2023, in Amsterdam. With lipid nanoparticles (LNPs) moving beyond mRNA vaccines, AlgiPharma is developing its technology to improve the delivery and efficacy of LNP therapeutics. Dr. Philip Rye, Chief Scientific Officer at AlgiPharma will […]
